Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonelokimab - MoonLake Immunotherapeutics

Next Previous
Drug Profile

Sonelokimab - MoonLake Immunotherapeutics

Alternative Names: ALX 0761; Anti-IL-17A/F Nanobody; M 1095; MSB-0010841; Nanobody® IL-17 A/F inhibitor; Sonelokinab

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ablynx
  • Developer Avillion; MoonLake Immunotherapeutics
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Single-domain antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hidradenitis suppurativa; Psoriatic arthritis
  • Phase II Axial spondyloarthritis; Palmoplantar pustulosis; Psoriasis
  • No development reported Ankylosing spondylitis

Most Recent Events

  • 10 Aug 2026 Efficacy and adverse events data form the phase III IZAR-1 trial in Psoriatic arthritis released by MoonLake Immunotherapeutic
  • 22 Jun 2026 FDA assigns PDUFA action date of (30/11/2026) for Sonelokimab for Hidradenitis suppurativa
  • 22 Jun 2026 MoonLake Immunotherapeutics plans to submit a request for priority review for Sonelokimab for Hidradenitis suppurativa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top